Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anil Abraham

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Breast Cancer Research and Treatment|May 26, 2019
Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT)Bassam Basulaiman, Arif Ali Awan, Dean Fergusson, et al.
Plos One|February 4, 2021
Optimising weight-loss interventions in cancer patients-A systematic review and network meta-analysisNathalie LeVasseur, Wei Cheng, Sasha Mazzarello, et al.
Journal of Bone Oncology|September 27, 2021
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michelle Liu, Carol Stober, et al.
BMJ Open|September 15, 2019
Community-based exercise for health promotion and secondary cancer prevention in Canada: protocol for a hybrid effectiveness-implementation studyMargaret L McNeely, Christopher Sellar, Tanya Williamson, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2020
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michael Ong, Carol Stober, et al.
International Journal of Cancer|June 9, 2025
Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trialJaqueline Munhoz, Marnie Newell, Gilbert Bigras, et al.
Cell Reports. Medicine|November 10, 2021
Genome profiles of pathologist-defined cell clusters by multiregional LCM and G&T-seq in one triple-negative breast cancer patientZhongyi Zhu, Weiwei Wang, Feng Lin, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast CancerJeffrey Q Cao, Brae Surgeoner, Mita Manna, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025Sandeep Sehdev, Anil Abraham Joy, Jean-François Boileau, et al.
Cancer Research Communications|October 22, 2025
Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast CancerAnil Abraham Joy, Nicholas Cheng, Karen A Gelmon, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Breast Cancer Research and Treatment|May 26, 2019
Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT)Bassam Basulaiman, Arif Ali Awan, Dean Fergusson, et al.
Plos One|February 4, 2021
Optimising weight-loss interventions in cancer patients-A systematic review and network meta-analysisNathalie LeVasseur, Wei Cheng, Sasha Mazzarello, et al.
Journal of Bone Oncology|September 27, 2021
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michelle Liu, Carol Stober, et al.
BMJ Open|September 15, 2019
Community-based exercise for health promotion and secondary cancer prevention in Canada: protocol for a hybrid effectiveness-implementation studyMargaret L McNeely, Christopher Sellar, Tanya Williamson, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2020
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michael Ong, Carol Stober, et al.
International Journal of Cancer|June 9, 2025
Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trialJaqueline Munhoz, Marnie Newell, Gilbert Bigras, et al.
Cell Reports. Medicine|November 10, 2021
Genome profiles of pathologist-defined cell clusters by multiregional LCM and G&T-seq in one triple-negative breast cancer patientZhongyi Zhu, Weiwei Wang, Feng Lin, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast CancerJeffrey Q Cao, Brae Surgeoner, Mita Manna, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025Sandeep Sehdev, Anil Abraham Joy, Jean-François Boileau, et al.
Cancer Research Communications|October 22, 2025
Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast CancerAnil Abraham Joy, Nicholas Cheng, Karen A Gelmon, et al.
Pageof 6